Outcomes
depression, Wexner constipation, anxiety, pain
REMISSION
Our primary outcome was the increases in oral morphine equivalent daily doses (OMEDDs) between the two groups; the daily doses of every eligible participants were recorded at baseline and on days 7, 14, 21, 30, 60, and 90 of this trial, and the dosage changes were calculated on this basis. Secondary outcomes included dynamic changes in BTcP and average VAS pain scores, relief of anxiety and depression symptoms, remission of OIC (determined by comparing Wexner constipation scores), and the acceptability and safety of the L‐TAMS regimen.